RxDoctor Payments Data

Kayleigh Galliher

Family Medicine · Mine Hill, NJNPI 1447921291

Payments from drug & device makers

$1,855in general payments, 2019–2025

Across 102 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$419
  • Corcept Therapeutics$384
  • AstraZeneca$338
  • Phathom Pharmaceuticals, Inc.$139
  • Bausch Health US, LLC$103
  • Pfizer$88
  • plus $384 from 9 others

What the payments were for

  • Food & beverage$1,855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$21,980
Medicare patients
124
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$19,809
MounjaroTirzepatide16$17,396
FarxigaDapagliflozin Propanediol20$15,443
Atorvastatin Calcium43$450
Pantoprazole Sodium32$361
Albuterol Sulfate HfaAlbuterol Sulfate16$359
Levothyroxine Sodium60$320
Escitalopram Oxalate33$281
Venlafaxine Hcl ErVenlafaxine Hcl15$201
Rosuvastatin Calcium20$177
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide13$156
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$147
Metformin Hcl16$145
Lisinopril30$143
Gabapentin11$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$419$19,80917 claims
Lilly USA, LLCMounjaro$63$17,39616 claims
AstraZenecaFarxiga$338$15,44320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Mine Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →